Galectin-9 in tumor biology: A jack of multiple trades

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1836, Issue 1, 2013, Pages 177-185

  Heusschen, Roy ^a,b   Griffioen, Arjan W ^a   Thijssen, Victor L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Cancer therapy; Galectin; Immune escape; Metastasis

Indexed keywords

ECALECTIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; MESSENGER RNA; RECOMBINANT ECALECTIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING AFFINITY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER THERAPY; CELL ADHESION; CELL CYCLE REGULATION; CELL MIGRATION; COLON CANCER; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GALECTIN 9 GENE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; LEUKEMIA; LIGAND BINDING; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MOLECULAR CLONING; MOLECULAR DYNAMICS; MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; TUMOR ESCAPE; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; GALECTINS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84878175699     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.04.006     Document Type: Review

References (113)

1. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., Gitt M.A., Hirabayashi J., Hughes C., Kasai K., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
2. Leffler H., Carlsson S., Hedlund M., Qian Y., Poirier F. Introduction to galectins. Glycoconj. J. 2004, 19:433-440.
3. Rabinovich G.A., Toscano M.A., Jackson S.S., Vasta G.R. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 2007, 17:513-520.
4. Rabinovich G.A., Toscano M.A. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 2009, 9:338-352.
5. Yang R.Y., Rabinovich G.A., Liu F.T. Galectins: structure, function and therapeutic potential. Expert Rev. Mol. Med. 2008, 10:e17.
6. Hughes R.C. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1999, 1473:172-185.
7. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5:29-41.
8. Wang J.L., Gray R.M., Haudek K.C., Patterson R.J. Nucleocytoplasmic lectins. Biochim. Biophys. Acta 2004, 1673:75-93.
9. Imaizumi Y., Sakaguchi M., Morishita T., Ito M., Poirier F., Sawamoto K., Okano H. Galectin-1 is expressed in early-type neural progenitor cells and down-regulates neurogenesis in the adult hippocampus. Mol. Brain 2011, 4:7.
10. Comte I., Kim Y., Young C.C., van der Harg J.M., Hockberger P., Bolam P.J., Poirier F., Szele F.G. Galectin-3 maintains cell motility from the subventricular zone to the olfactory bulb. J. Cell Sci. 2011, 124:2438-2447.
11. Cardenas Delgado V.M., Nugnes L.G., Colombo L.L., Troncoso M.F., Fernandez M.M., Malchiodi E.L., Frahm I., Croci D.O., Compagno D., Rabinovich G.A., Wolfenstein-Todel C., Elola M.T. Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J. 2011, 25:242-254.
12. Markowska A.I., Liu F.T., Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 2010, 207:1981-1993.
13. Thijssen V.L., Postel R., Brandwijk R.J., Dings R.P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L.G., Bakkers J., Mayo K.H., Poirier F., Griffioen A.W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15975-15980.
14. Ilarregui J.M., Croci D.O., Bianco G.A., Toscano M.A., Salatino M., Vermeulen M.E., Geffner J.R., Rabinovich G.A. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009, 10:981-991.
15. Blois S.M., Ilarregui J.M., Tometten M., Garcia M., Orsal A.S., Cordo-Russo R., Toscano M.A., Bianco G.A., Kobelt P., Handjiski B., Tirado I., Markert U.R., Klapp B.F., Poirier F., Szekeres-Bartho J., Rabinovich G.A., Arck P.C. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 2007, 13:1450-1457.
16. Heusschen R., Freitag N., Tirado-González I., Barrientos G., Moschansky P., Muñoz-Fernández R., Leno-Durán E., Klapp B.F., Thijssen V.L., Blois S.M. Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological human pregnancy. Biol. Reprod. 2013, 88:22.
17. Elad-Sfadia G., Haklai R., Balan E., Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 2004, 279:34922-34930.
18. Paz A., Haklai R., Elad-Sfadia G., Ballan E., Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001, 20:7486-7493.
19. Nangia-Makker P., Honjo Y., Sarvis R., Akahani S., Hogan V., Pienta K.J., Raz A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156:899-909.
20. Yang R.Y., Liu F.T. Galectins in cell growth and apoptosis. Cell. Mol. Life Sci. 2003, 60:267-276.
21. Hughes R.C. Galectins as modulators of cell adhesion. Biochimie 2001, 83:667-676.
22. Kuwabara I., Sano H., Liu F.T. Functions of galectins in cell adhesion and chemotaxis. Methods Enzymol. 2003, 363:532-552.
23. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739.
24. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L., Rabinovich G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241-251.
25. Tureci O., Schmitt H., Fadle N., Pfreundschuh M., Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J. Biol. Chem. 1997, 272:6416-6422.
26. Wada J., Ota K., Kumar A., Wallner E.I., Kanwar Y.S. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J. Clin. Invest. 1997, 99:2452-2461.
27. Leal-Pinto E., Tao W., Rappaport J., Richardson M., Knorr B.A., Abramson R.G. Molecular cloning and functional reconstitution of a urate transporter/channel. J. Biol. Chem. 1997, 272:617-625.
28. Matsushita N., Nishi N., Seki M., Matsumoto R., Kuwabara I., Liu F.T., Hata Y., Nakamura T., Hirashima M. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J. Biol. Chem. 2000, 275:8355-8360.
29. Kimura K., Wakamatsu A., Suzuki Y., Ota T., Nishikawa T., Yamashita R., Yamamoto J., Sekine M., Tsuritani K., Wakaguri H., Ishii S., Sugiyama T., Saito K., Isono Y., Irie R., Kushida N., Yoneyama T., Otsuka R., Kanda K., Yokoi T., Kondo H., Wagatsuma M., Murakawa K., Ishida S., Ishibashi T., Takahashi-Fujii A., Tanase T., Nagai K., Kikuchi H., Nakai K., Isogai T., Sugano S. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006, 16:55-65.
30. Oh J.H., Yang J.O., Hahn Y., Kim M.R., Byun S.S., Jeon Y.J., Kim J.M., Song K.S., Noh S.M., Kim S., Yoo H.S., Kim Y.S., Kim N.S. Transcriptome analysis of human gastric cancer. Mamm. Genome 2005, 16:942-954.
31. Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E., Jones S.J., Marra M.A. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16899-16903. Mammalian Gene Collection Program Team.
32. Bidon N., Brichory F., Hanash S., Bourguet P., Dazord L., Le Pennec J.P. Two messenger RNAs and five isoforms for Po66-CBP, a galectin-8 homolog in a human lung carcinoma cell line. Gene 2001, 274:253-262.
33. Bidon N., Brichory F., Bourguet P., Le Pennec J.P., Dazord L. Galectin-8: a complex sub-family of galectins (review). Int. J. Mol. Med. 2001, 8:245-250.
34. Ahmed H., Banerjee P.P., Vasta G.R. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem. Biophys. Res. Commun. 2007, 358:241-246.
35. Chabot S., Kashio Y., Seki M., Shirato Y., Nakamura K., Nishi N., Nakamura T., Matsumoto R., Hirashima M. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 2002, 12:111-118.
36. Spitzenberger F., Graessler J., Schroeder H.E. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie 2001, 83:851-862.
37. Bi S., Earl L.A., Jacobs L., Baum L.G. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J. Biol. Chem. 2008, 283:12248-12258.
38. Earl L.A., Bi S., Baum L.G. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology 2011, 21:6-12.
39. Hirashima M., Kashio Y., Nishi N., Yamauchi A., Imaizumi T.A., Kageshita T., Saita N., Nakamura T. Galectin-9 in physiological and pathological conditions. Glycoconj. J. 2004, 19:593-600.
40. Thijssen V.L., Hulsmans S., Griffioen A.W. The galectin profile of the endothelium; altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 2008, 172:545-553.
41. Lipkowitz M.S., Leal-Pinto E., Cohen B.E., Abramson R.G. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj. J. 2004, 19:491-498.
42. Asakura H., Kashio Y., Nakamura K., Seki M., Dai S., Shirato Y., Abedin M.J., Yoshida N., Nishi N., Imaizumi T., Saita N., Toyama Y., Takashima H., Nakamura T., Ohkawa M., Hirashima M. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J. Immunol. 2002, 169:5912-5918.
43. Yoshida H., Teraoka M., Nishi N., Nakakita S., Nakamura T., Hirashima M., Kamitori S. X-ray structures of human galectin-9 C-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. J. Biol. Chem. 2010, 285:36969-36976.
44. Nagae M., Nishi N., Murata T., Usui T., Nakamura T., Wakatsuki S., Kato R. Structural analysis of the recognition mechanism of poly-N-acetyllactosamine by the human galectin-9N-terminal carbohydrate recognition domain. Glycobiology 2009, 19:112-117.
45. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.
46. Katoh S., Ishii N., Nobumoto A., Takeshita K., Dai S.Y., Shinonaga R., Niki T., Nishi N., Tominaga A., Yamauchi A., Hirashima M. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. Respir. Crit. Care Med. 2007, 176:27-35.
47. Matsuura A., Tsukada J., Mizobe T., Higashi T., Mouri F., Tanikawa R., Yamauchi A., Hirashima M., Tanaka Y. Intracellular galectin-9 activates inflammatory cytokines in monocytes. Genes Cells 2009, 14:511-521.
48. Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 2001, 127:375-386.
49. Kasamatsu A., Uzawa K., Nakashima D., Koike H., Shiiba M., Bukawa H., Yokoe H., Tanzawa H. Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int. J. Mol. Med. 2005, 16:269-273.
50. Irie A., Yamauchi A., Kontani K., Kihara M., Liu D., Shirato Y., Seki M., Nishi N., Nakamura T., Yokomise H., Hirashima M. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 2005, 11:2962-2968.
51. Kageshita T., Kashio Y., Yamauchi A., Seki M., Abedin M.J., Nishi N., Shoji H., Nakamura T., Ono T., Hirashima M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 2002, 99:809-816.
52. Danguy A., Camby I., Kiss R. Galectins and cancer. Biochim. Biophys. Acta 2002, 1572:285-293.
53. van den Brule F., Califice S., Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj. J. 2004, 19:537-542.
54. Liang M., Ueno M., Oomizu S., Arikawa T., Shinonaga R., Zhang S., Yamauchi A., Hirashima M. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:899-907.
55. Zhang Z.Y., Dong J.H., Chen Y.W., Wang X.Q., Li C.H., Wang J., Wang G.Q., Li H.L., Wang X.D. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2012, 13:2503-2509.
56. Lahm H., Hoeflich A., Andre S., Sordat B., Kaltner H., Wolf E., Gabius H.J. Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frame-shift mutations for protein sequence truncations in the second functional lectin domain. Int. J. Oncol. 2000, 17:519-524.
57. Imaizumi T., Kumagai M., Sasaki N., Kurotaki H., Mori F., Seki M., Nishi N., Fujimoto K., Tanji K., Shibata T., Tamo W., Matsumiya T., Yoshida H., Cui X.-F., Takanashi S., Hanada K., Okumura K., Yagihashi S., Wakabayashi K., Nakamura T., Hirashima M., Satoh K. Interferon-{gamma} stimulates the expression of galectin-9 in cultured human endothelial cells. J. Leukoc. Biol. 2002, 72:486-491.
58. Alam S., Li H., Margariti A., Martin D., Zampetaki A., Habi O., Cockerill G., Hu Y., Xu Q., Zeng L. Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3. J. Biol. Chem. 2011, 286:44211-44217.
59. Yoshida H., Imaizumi T., Kumagai M., Kimura K., Satoh C., Hanada N., Fujimoto K., Nishi N., Tanji K., Matsumiya T., Mori F., Cui X.F., Tamo W., Shibata T., Takanashi S., Okumura K., Nakamura T., Wakabayashi K., Hirashima M., Sato Y., Satoh K. Interleukin-1beta stimulates galectin-9 expression in human astrocytes. Neuroreport 2001, 12:3755-3758.
60. Saita N., Goto E., Yamamoto T., Cho I., Tsumori K., Kohrogi H., Maruo K., Ono T., Takeya M., Kashio Y., Nakamura K., Hirashima M. Association of galectin-9 with eosinophil apoptosis. Int. Arch. Allergy Immunol. 2002, 128:42-50.
61. van den Brule F., Califice S., Garnier F., Fernandez P.L., Berchuck A., Castronovo V. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab. Invest. 2003, 83:377-386.
62. Espelt M.V., Croci D.O., Bacigalupo M.L., Carabias P., Manzi M., Elola M.T., Muñoz M.C., Dominici F.P., Wolfenstein-Todel C., Rabinovich G.A., Troncoso M.F. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 2011, 53:2097-2106.
63. +) T cells and reduced cancer cell adherence. Clin. Exp. Metastasis 2012, 29:561-572.
64. Thijssen V.L., Barkan B., Shoji H., Aries I.M., Mathieu V., Deltour L., Hackeng T.M., Kiss R., Kloog Y., Poirier F., Griffioen A.W. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010, 70:6216-6224.
65. Liu F.T., Yang R.Y., Saegusa J., Chen H.Y., Hsu D.K. Galectins in regulation of apoptosis. Adv. Exp. Med. Biol. 2011, 705:431-442.
66. Kobayashi T., Kuroda J., Ashihara E., Oomizu S., Terui Y., Taniyama A., Adachi S., Takagi T., Yamamoto M., Sasaki N., Horiike S., Hatake K., Yamauchi A., Hirashima M., Taniwaki M. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 2010, 24:843-850.
67. Kashio Y., Nakamura K., Abedin M.J., Seki M., Nishi N., Yoshida N., Nakamura T., Hirashima M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 2003, 170:3631-3636.
68. Lu L.H., Nakagawa R., Kashio Y., Ito A., Shoji H., Nishi N., Hirashima M., Yamauchi A., Nakamura T. Characterization of galectin-9-induced death of Jurkat T cells. J. Biochem. 2007, 141:157-172.
69. Su E.W., Bi S., Kane L.P. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 2011, 21:1258-1265.
70. Vas V., Fajka-Boja R., Ion G., Dudics V., Monostori E., Uher F. Biphasic effect of recombinant galectin-1 on the growth and death of early hematopoietic cells. Stem Cells 2005, 23:279-287.
71. Califice S., Castronovo V., Bracke M., van den Brule F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23:7527-7536.
72. Kim K.S., Kang K.W., Seu Y.B., Baek S.H., Kim J.R. Interferon-gamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells. Mech. Ageing Dev. 2009, 130:179-188.
73. Zhang F., Zheng M., Qu Y., Li J., Ji J., Feng B., Lu A., Li J., Wang M., Liu B. Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Mol. Biol. Rep. 2009, 36:823-830.
74. Nobumoto A., Nagahara K., Oomizu S., Katoh S., Nishi N., Takeshita K., Niki T., Tominaga A., Yamauchi A., Hirashima M. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008, 18:735-744.
75. Friedrichs J., Manninen A., Muller D.J., Helenius J. Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and -IV. J. Biol. Chem. 2008, 283:32264-32272.
76. Sanchez-Ruderisch H., Detjen K.M., Welzel M., Andre S., Fischer C., Gabius H.J., Rosewicz S. Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor alpha(5)beta(1)-integrin. Cell Death Differ. 2011, 18:806-816.
77. Kluza E., Jacobs I., Hectors S.J., Mayo K.H., Griffioen A.W., Strijkers G.J., Nicolay K. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control. Release 2012, 158:207-214.
78. Kluza E., van der Schaft D.W., Hautvast P.A., Mulder W.J., Mayo K.H., Griffioen A.W., Strijkers G.J., Nicolay K. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010, 10:52-58.
79. Rabinovich G.A., Croci D.O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012, 36:322-335.
80. Hirashima M. Ecalectin/galectin-9, a novel eosinophil chemoattractant: its function and production. Int. Arch. Allergy Immunol. 2000, 122(Suppl. 1):6-9.
81. Gatault S., Legrand F., Delbeke M., Loiseau S., Capron M. Involvement of eosinophils in the anti-tumor response. Cancer Immunol. Immunother. 2012, 61:1527-1534.
82. Wedemeyer J., Vosskuhl K. Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract. Res. Clin. Gastroenterol. 2008, 22:537-549.
83. Samoszuk M. Eosinophils and human cancer. Histol. Histopathol. 1997, 12:807-812.
84. Munitz A., Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy 2004, 59:268-275.
85. Seki M., Oomizu S., Sakata K.M., Sakata A., Arikawa T., Watanabe K., Ito K., Takeshita K., Niki T., Saita N., Nishi N., Yamauchi A., Katoh S., Matsukawa A., Kuchroo V., Hirashima M. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 2008, 127:78-88.
86. Wang F., He W., Yuan J., Wu K., Zhou H., Zhang W., Chen Z.K. Activation of Tim-3-galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl. Immunol. 2008, 19:12-19.
87. + alloreactive T cell and prolongs survival of skin graft. Cell. Immunol. 2007, 250:68-74.
88. Bi S., Hong P.W., Lee B., Baum L.G. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. 2011, 108:10650-10655.
89. Keryer-Bibens C., Pioche-Durieu C., Villemant C., Souquère S., Nishi N., Hirashima M., Middeldorp J., Busson P. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006, 6:283.
90. + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 2008, 181:7660-7669.
91. Nobumoto A., Oomizu S., Arikawa T., Katoh S., Nagahara K., Miyake M., Nishi N., Takeshita K., Niki T., Yamauchi A., Hirashima M. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin. Immunol. 2009, 130:322-330.
92. Nangia-Makker P., Wang Y., Raz T., Tait L., Balan V., Hogan V., Raz A. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int. J. Cancer 2010, 127:2530-2541.
93. Fainaru O., Almog N., Yung C.W., Nakai K., Montoya-Zavala M., Abdollahi A., D'Amato R., Ingber D.E. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J. 2010, 24:1411-1418.
94. Brandwijk R.J., Dings R.P., van der Linden E., Mayo K.H., Thijssen V.L., Griffioen A.W. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem. Biophys. Res. Commun. 2006, 349:1073-1078.
95. Ito K., Scott S.A., Cutler S., Dong L.F., Neuzil J., Blanchard H., Ralph S.J. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 2011, 14:293-307.
96. Glinskii O.V., Sud S., Mossine V.V., Mawhinney T.P., Anthony D.C., Glinsky G.V., Pienta K.J., Glinsky V.V. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine. Neoplasia 2012, 14:65-73.
97. Liu H.Y., Huang Z.L., Yang G.H., Lu W.Q., Yu N.R. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J. Gastroenterol. 2008, 14:7386-7391.
98. Nangia-Makker P., Hogan V., Honjo Y., Baccarini S., Tait L., Bresalier R., Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J. Natl. Cancer Inst. 2002, 94:1854-1862.
99. Wiersma V.R., de Bruyn M., Helfrich W., Bremer E. Therapeutic potential of Galectin-9 in human disease. Med. Res. Rev. 2011, 33(Suppl 1):E102-E126.
100. Seki M., Sakata K.M., Oomizu S., Arikawa T., Sakata A., Ueno M., Nobumoto A., Niki T., Saita N., Ito K., Dai S.Y., Katoh S., Nishi N., Tsukano M., Ishikawa K., Yamauchi A., Kuchroo V., Hirashima M. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum. 2007, 56:3968-3976.
101. Kuroda J., Yamamoto M., Nagoshi H., Kobayashi T., Sasaki N., Shimura Y., Horiike S., Kimura S., Yamauchi A., Hirashima M., Taniwaki M. Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol. Cancer Res. 2010, 8:994-1001.
102. Kadowaki T., Arikawa T., Shinonaga R., Oomizu S., Inagawa H., Soma G., Niki T., Hirashima M. Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages. Clin. Immunol. 2012, 142:296-307.
103. Collins P.M., Oberg C.T., Leffler H., Nilsson U.J., Blanchard H. Taloside inhibitors of galectin-1 and galectin-3. Chem. Biol. Drug Des. 2012, 79:339-346.
104. Stannard K.A., Collins P.M., Ito K., Sullivan E.M., Scott S.A., Gabutero E., Darren Grice I., Low P., Nilsson U.J., Leffler H., Blanchard H., Ralph S.J. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett. 2010, 299:95-110.
105. Ingrassia L., Camby I., Lefranc F., Mathieu V., Nshimyumukiza P., Darro F., Kiss R. Anti-galectin compounds as potential anti-cancer drugs. Curr. Med. Chem. 2006, 13:3513-3527.
106. Salomonsson E., Thijssen V.L., Griffioen A.W., Nilsson U.J., Leffler H. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J. Biol. Chem. 2011, 286:13801-13804.
107. Solís D., Maté M.J., Lohr M., Ribeiro J.P., López-Merino L., André S., Buzamet E., Cañada F.J., Kaltner H., Lensch M., Ruiz F.M., Haroske G., Wollina U., Kloor M., Kopitz J., Sáiz J.L., Menéndez M., Jiménez-Barbero J., Romero A., Gabius H.J. N-domain of human adhesion/growth-regulatory galectin-9: preference for distinct conformers and non-sialylated N-glycans and detection of ligand-induced structural changes in crystal and solution. Int. J. Biochem. Cell Biol. 2010, 42:1019-1029.
108. Tanikawa R., Tanikawa T., Hirashima M., Yamauchi A., Tanaka Y. Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem. Biophys. Res. Commun. 2010, 394:317-322.
109. Pioche-Durieu C., Keryer C., Souquere S., Bosq J., Faigle W., Loew D., Hirashima M., Nishi N., Middeldorp J., Busson P. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J. Virol. 2005, 79:13326-13337.
110. Pelletier I., Hashidate T., Urashima T., Nishi N., Nakamura T., Futai M., Arata Y., Kasai K., Hirashima M., Hirabayashi J., Sato S. Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between L. major and host cells. J. Biol. Chem. 2003, 278:22223-22230.
111. Nishi N., Itoh A., Shoji H., Miyanaka H., Nakamura T. Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology 2006, 16:15C-20C.
112. Miyanishi N., Nishi N., Abe H., Kashio Y., Shinonaga R., Nakakita S., Sumiyoshi W., Yamauchi A., Nakamura T., Hirashima M., Hirabayashi J. Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family. Glycobiology 2007, 17:423-432.
113. Niki T., Tsutsui S., Hirose S., Aradono S., Sugimoto Y., Takeshita K., Nishi N., Hirashima M. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J. Biol. Chem. 2009, 284:32344-32352.